Plant Name: Allium chinense
Taxonomic Information:
Plant ID: NPO8321
Plant Latin Name: Allium chinense
Taxonomy Genus: Allium
Taxonomy Family: Amaryllidaceae
Plant External Links:
NCBI TaxonomyDB:
130426
Plant-of-the-World-Online:
527818-1
Used in Medicines:
Country/Region:
Indonesia; India; Malaysia; Vietnam; China; ThailandTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Astringent; Carminative; Expectorant
Geographical Distribution:
Bangladesh; Cuba; Indonesia; India; South Africa; Malaysia; Vietnam; China; Thailand; Japan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; | |
| TSHR; | |
| TRPA1; | |
| MIF; TERT; ADK; HPGD; ALDH1A1; | |
| CTSL; CTSB; | |
| STAT6; | |
| SLC28A2; SLC28A3; SLC28A1; | |
| SMN1;SMN2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CTSL | Cathepsin L | P07711 | CHEMBL3837 |
| Cysteine protease | CTSB | Cathepsin B | P07858 | CHEMBL4072 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.817E-08 | 1.227E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 6.752E-08 | 2.100E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 9.167E-07 | 1.815E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 9.167E-07 | 1.815E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 9.167E-07 | 1.815E-03 | SLC28A2, SLC28A3 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 2.748E-06 | 3.325E-03 | SLC28A1, SLC28A3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 2.748E-06 | 3.325E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.748E-06 | 3.325E-03 | ADORA1, ADORA2A |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 9.348E-06 | 9.252E-03 | ADORA1, ADORA2A, ADORA3, HPGD, LMNA, MIF, STAT6, TERT, TSHR |
| CC | GO:0044464; cell part | GO:0036021; endolysosome lumen | 9.151E-06 | 9.252E-03 | CTSB, CTSL |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.866E-05 | 2.045E-02 | ADORA1, ADORA2A, ADORA3, SLC28A1, SLC28A2, SLC28A3, TRPA1, TSHR |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 3.286E-05 | 2.045E-02 | ADORA1, ADORA2A |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 6.015E-05 | 3.447E-02 | SMN1, SMN2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.183E-05 | 4.294E-02 | ADORA2A, HPGD, MIF, SMN1, SMN2, STAT6, TERT, TRPA1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.185E-04 | 4.146E-03 | ADORA2A, ADORA3, ADORA1, TSHR |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.996E-04 | 5.244E-03 | CTSL, LMNA, CTSB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.360E-04 | 9.753E-03 | ADORA2A, ADORA1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.277E-03 | 1.117E-02 | ADORA1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04924 | Renin secretion | 1.664E-03 | 1.165E-02 | ADORA1, CTSB |
| 09150 Organismal Systems | 09151 Immune system | hsa04612 | Antigen processing and presentation | 2.398E-03 | 1.399E-02 | CTSL, CTSB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.711E-03 | 2.621E-02 | ADORA3, ADORA1 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04142 | Lysosome | 5.991E-03 | 2.621E-02 | CTSL, CTSB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.080E-02 | 3.998E-02 | ADORA3, ADORA1 |
| 09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 1.142E-02 | 3.998E-02 | SMN2, SMN1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; TRPA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
